New Insights into Inflammatory Bowel Disease Pathophysiology: Paving the Way for Novel Therapeutic Targets
Tommaso Stefanelli, Alberto Malesci, Alessandro Repici, Stefania Vetrano and Silvio Danese
Affiliation: Division of Gastroenterology,Istituto Clinico Humanitas-IRCCS in Gastroenterology, Viale Manzoni,Rozzano, Milan, Italy.
Keywords: Crohn disease, NSAIDs, ulcerative colitis, Th17 cells, Mycobacterium paratuberculosis
The etiopathogenesis of Crohns disease (CD) and ulcerative Colitis (UC), the two major forms of inflammatory bowel disease (IBD), is still unknown. Although the exact cause and mechanisms of both IBD have yet to be completely understood, it is widely accepted that both CD and UC result from an inappropriate immune response that occurs in genetically susceptible individuals as the result of a complex interaction among environmental factors, microbial factors, and the intestinal immune system. In the last few years a tremendous advance in knowledge of the mechanisms underling intestinal inflammation in IBD has been achieved, leading to new therapeutic targets and novel drugs. These new therapeutic weapons have been specifically designed to selective shut down intestinal inflammation at different levels. Aim of this review is to summarize the recent advances in IBD pathophysiology and the new therapeutic targets and drugs that are changing the IBD clinical management.
Rights & PermissionsPrintExport